Comparison of HbA1c and blood pressures in treatment group and placebo group between baseline, at three-months treatment, and at six- to nine-months washout.

Table 8: Comparison of HbA1c and blood pressures in treatment group and placebo group between baseline, at three-months treatment, and at six- to nine-months washout.

Parameters	Treatment group (n = 12)			Placebo group (n = 18)
Parameters	Mean ± SD	F	P-value	Mean ± SD	F	P-value
HbA1c (%)
Baseline	9.30 ± 2.09	3.150	0.063	8.52 ± 1.73	0.512	0.604
Week 12	8.90 ± 1.47			8.44 ± 1.80
Week 36	8.58 ± 1.46			8.25 ± 1.32
SBP (mmHg)
Baseline	138.72 ± 16.05	1.329	0.285	135.37 ± 10.19	1.937	0.160
Week 12	131.94 ± 10.03			131.15 ± 11.20
Week 36	132.17 ± 12.71			138.00 ± 14.96
DBP (mmHg)
Baseline	75.60 ± 7.83	1.532	0.238	77.97 ± 7.18	2.225	0.124
Week 12	72.56 ± 11.20			75.34 ± 8.61
Week 36	77.08 ± 11.54			78.96 ± 9.24

Repeated measures ANOVA. Assumptions fulfilled. n: number of patients; HbA1c: Haemoglobin A1c; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; Week 12: at 12 weeks of treatment; Week 36: 24 weeks after treatment cessation.